Partial
Needs Verification
Patient Risk:
Moderate
Summary
Many mechanistic and glucose-lowering claims are supported by label sections 11 and 12; however, several substantive efficacy/timing/discontinuation and GI-experience claims are not supported by the supplied label text, and one kidney-function variability claim is contradicted. The audit input also lacks contraindications/boxed warning/pregnancy/dosing sections, limiting full compliance confirmation.
Category Scores
Accurate Statements
Ozempic contains semaglutide.
11 DESCRIPTION
Ozempic is a GLP-1 receptor agonist.
12.1 Mechanism of Action
Semaglutide stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner.
12.1 Mechanism of Action
Semaglutide reduces fasting and postprandial blood glucose.
12.2 Pharmacodynamics (Fasting and Postprandial Glucose)
Semaglutide causes a delay of early postprandial gastric emptying and reduces the rate at which glucose appears in circulation postprandially.
12.1 Mechanism of Action; 12.2 Pharmacodynamics (Gastric emptying)
Hypoglycemia risk is increased when Ozempic is used with an insulin secretagogue (e.g., sulfonylurea) or insulin; consider reducing concomitant secretagogue/insulin to reduce hypoglycemia risk.
5.5 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin; 7.1 Concomitant Use with an Insulin Secretagogue or with Insulin
Hypoglycemia is more likely with Ozempic combined with insulin or sulfonylureas.
5.5; 7.1
Ozempic targets post-meal effects (postprandial glucose; glucagon secretion) as well as fasting glucose.
12.2 Pharmacodynamics (Fasting and Postprandial Glucose; Glucagon Secretion)
Unsupported Statements
Many people see blood sugar improvement within weeks of Ozempic treatment.
No provided label text supports a generalizable “many people within weeks” claim; supplied label text provides trial results but not this patient-experience generalization.
Ozempic can have variable response based on meal patterns.
No supplied label text supports meal-pattern variability as a determinant of response.
Ozempic response can vary based on baseline insulin resistance.
No supplied label text supports baseline insulin resistance as a determinant of response.
Gastrointestinal side effects are common with GLP-1 receptor agonists, including Ozempic; GI effects can indirectly affect food intake and thus glucose control; especially relevant early or after dose increases.
The supplied label text excerpts do not support these generalized frequency/timing/food-intake mechanism statements for Ozempic.
When Ozempic treatment stops, its glucose-lowering effects wear off; blood sugar control often worsens again; diabetes management usually requires reassessment of the medication plan with a clinician.
No supplied label text supports discontinuation “wear off”/“worsens again”/“usually requires reassessment” statements.
Ozempic's mechanism differs from insulin-based approaches that replace insulin directly.
No supplied label text supports this comparative mechanism claim.
Ozempic's mechanism differs from drugs that increase insulin release or reduce glucose production in other ways.
No supplied label text supports this comparative mechanism claim.
Contradictions
High
AI Statement
Ozempic response can vary based on kidney function.
Label Reference
14.1 Glycemic Control Trials in Adults with Type 2 Diabetes Mellitus: “The efficacy of OZEMPIC was not impacted… level of renal function impairment.”
Important Omissions
Boxed warning, contraindications, and full safety/precaution content were not provided in the audit input for evaluation against the AI claims (e.g., thyroid C-cell tumors, acute pancreatitis, gastroparesis recommendation, other labeled warnings).
Importance:
Moderate
Dosage and administration details (including any renal dosing/adjustment specifics) were not included in the provided label excerpts; several AI claims relate indirectly to safety management but cannot be fully assessed for dosing/administration compliance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported discontinuation and GI-experience claims could mislead patient expectations; the kidney-function variability claim directly conflicts with the provided label efficacy statement.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Verification
Primary Issue
Several substantive claims are unsupported by the supplied label excerpts (discontinuation effects, GI frequency/timing/food-intake mechanism, patient-experience timelines) and one kidney-function response claim is contradicted.
Suggested Improvement
Remove or rephrase unsupported/contradicted claims; base statements on the supplied label sections (11, 12, 5.5, 7.1, 14.1). Additionally, re-run the audit with the full label text sections for boxed warning, contraindications, dosing/administration, and discontinuation guidance to confirm overall FDA-label alignment.